Drug Trend Report 2020: Using analytics to guide pandemic preparedness and support | CVS Health

Using analytics to guide pandemic preparedness and support

COVID-19 may be the most disruptive force any of us will ever experience. The last thing plan members needed was angst when it came to their prescriptions. We used predictive analytics to avoid disruptions — particularly within our pharmaceutical supply chain:

  • Adapted our supply chain to account for early COVID-19 spikes in primary supply chain locations like Northern Italy, India and China.

  • Secured supply and implemented quantity limits on drugs like hydroxychloroquine and albuterol — when there were some early suggestions that they had a role to play in COVID-19 — to prevent unnecessary stockpiling. We did not want to trade one public health crisis for another.

Hydroxychloroquine and chloroquine demand during the pandemic

Hydroxychloroquine and chloroquine demand during the pandemic

Albuterol demand during the pandemic

Albuterol demand during the pandemic

Thanks to public health measures widely put in place for COVID-19, such as physical distancing and mask-wearing, and more members than ever getting vaccinated, the 2020 flu season in the United States all but disappeared. That’s a behavioral change we hope continues into the future.

A graphic with three parts. Part one: Q1 2020 to Q1 2021: more than 37 percent decrease in flu-related acute medications. Part two: Q4 2019 to Q4 2020: more than 45 percent decrease in flu-related acute medications. Part three: 56 percent increase in retail pharmacy flu vaccinations for 2020 to 2021 season over prior year.

As the pharmacy benefit management (PBM) part of CVS Health, we stay motivated by the power and promise to help all our clients and members return to normalcy as we move closer to the end of the pandemic. That includes connecting them to the health services available through our enterprise.

A graphic with two parts. Part one: As of April 22, 2021, more than 10 million COVID-19 vaccines were administered. Part two: As of April 22, 2021, more than 15 million COVID-19 tests were administered.